Related Experiment Video

Updated: Jul 25, 2025

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
08:49

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

826

Cardiorenal interactions in heart failure: insights from recent therapeutic advances

Kevin Damman1, Jeffrey Testani2

  • 1University of Groningen, Department of Cardiology, University Medical Center Groningen, Hanzeplein 1, Groningen 9713GZ, The Netherlands.

Cardiovascular Research
|June 26, 2023
PubMed

Insights

New drug classes, including SGLT2 inhibitors and GLP-1 RAs, show promise in preventing and treating heart failure, particularly in high-risk patients with diabetes and kidney disease.

Area of Science:

  • Cardiology
  • Nephrology
  • Endocrinology

Background:

  • Heart failure significantly impacts quality of life, mortality, and healthcare costs.
  • Effective prevention and treatment strategies for heart failure are crucial.
  • Cardiovascular disease progression often leads to heart failure.

Purpose of the Study:

  • To evaluate the role of novel therapeutic agents in managing heart failure.
  • To assess the effectiveness of SGLT2i, GLP-1-RAs, and MRAs in cardiorenal disease.
  • To explore the impact of these drugs on cardiovascular and renal outcomes.

Main Methods:

  • Focus on high-risk patient populations with diabetes, chronic kidney disease, and/or heart failure.
  • Analysis of clinical data on sodium-glucose co-transporter 2 inhibitors (SGLT2i).
  • Review of studies involving glucagon-like peptide 1 receptor agonists (GLP-1-RAs) and non-steroidal mineralocorticoid receptor antagonists (MRAs).

Main Results:

  • SGLT2i have demonstrated efficacy across all heart failure subtypes.
  • GLP-1-RAs are effective in reducing cardiovascular events in diabetic patients.
  • These drug classes improve cardiovascular and renal endpoints in the cardiorenal continuum.

Conclusions:

  • Novel therapies, including SGLT2i, GLP-1-RAs, and MRAs, are advancing heart failure treatment.
  • These agents offer significant benefits for patients with cardiorenal disease and diabetes.
  • Further research is ongoing to fully elucidate the role of MRAs and GLP-1-RAs in established heart failure.

Keywords:
CardiorenalGLP-1-RAHeart failureMRASGLT2i

More Related Videos

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.6K
Normothermic Cardiac Arrest and Cardiopulmonary Resuscitation: A Mouse Model of Ischemia-Reperfusion Injury10:25

Normothermic Cardiac Arrest and Cardiopulmonary Resuscitation: A Mouse Model of Ischemia-Reperfusion Injury

Published on: August 30, 2011

18.2K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
467
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
15
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
425
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
18
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
640